If Menactra (MCV4) is inadvertently given by the subcutaneous route rather than the intramuscular route, how should this be managed?
In the package insert, the vaccine manufacturer recommends revaccination. However, for the last 6 months CDC has conducted a study on laboratory samples on 30 – 40 children who received MCV4 by the subcutaneous route. It appears that there is an adequate immune response. Therefore we are not recommending revaccination at this time. An article will be published soon in the MMWR regarding this. The best way to avoid this problem is to give the vaccine by the correct route – intramuscular.
Related Questions
- If Menactra (MCV4) is inadvertently given by the subcutaneous route rather than the intramuscular route, how should this be managed?
- What should we do if Menactra is administered by the subcutaneous route instead of the intramuscular route?
- What should be done if the MMR is inadvertently given Intramuscular (IM) instead of subcutaneous (SQ)?
